How this prostate cancer treatment can help men live longer
A major Australian-led clinical trial has found that adding the drug darolutamide to standard prostate cancer treatments significantly reduces the risk of relapse in high-risk patients. Researchers suggest this could change the standard of care and improve survival rates for thousands of men.
Why it matters
This finding represents a potential breakthrough in oncology, offering a more effective treatment pathway for aggressive prostate cancer that could save many lives.
Save You have reached your maximum number of saved items.
Remove items from your saved list to add more.
Gift Gift icon 0 / 3 No gift articles left
You've used all of your gift articles. 3 more will become available on the 1st of every month.
Share A A A A major Australian-led prostate cancer trial found a hormone-blocking drug dramatically reduced the risk of relapse among very high-risk men, prompting calls to change the standard of care for these patients and potentially save thousands of lives.
Adding the medication darolutamide (Nubeqa) to standard therapies for men with aggressive or treatment-resistant prostate cancer led to a 58 per cent drop in the cancer relapsing and spreading to other organs and tissue four years later, the researchers of the global phase 3 trial reported.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in